Free Trial
LON:AGL

ANGLE 9/9/2025 Earnings Report

ANGLE logo
GBX 1.80 -0.10 (-5.26%)
As of 11:22 AM Eastern

ANGLE EPS Results

Actual EPS
-GBX 2.87
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ANGLE Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ANGLE Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

ANGLE Earnings Headlines

Why Wall Street is piling into the “Debasement Trade”
Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman Sachs Vice President Dr. David Eifrig, it could have major implications for your money. In his new free report, Dr. Eifrig explains how this move could impact everyday investors and why multiple financial storms are converging right now.tc pixel
Discovering UK Penny Stocks: ANGLE And 2 Other Top Picks
See More ANGLE Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ANGLE? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ANGLE and other key companies, straight to your email.

About ANGLE

ANGLE (LON:AGL), a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

View ANGLE Profile

More Earnings Resources from MarketBeat